IL-5 was identified as a target to prevent or blunt eosinophil-mediated inflammation in patients with asthma, leading to the development of humanized anti-IL-5 mAb such as mepolizumab, reslizumab and benralizumab (Long, 2009; Molfino et al., 2012). This evidence concerns the gene IL5 and asthma.